Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(50%)
Results Posted
50%(1 trials)

Phase Distribution

Ph not_applicable
3
50%
Ph phase_3
2
33%
Ph phase_4
1
17%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
3(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Recruiting3
Completed2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (33.3%)
Phase 41 (16.7%)
N/A3 (50.0%)

Trials by Status

not_yet_recruiting117%
completed233%
recruiting350%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_4

Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain

NCT07451431
recruitingnot_applicable

The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia

NCT07157852
recruitingnot_applicable

Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA

NCT06328062
not_yet_recruitingnot_applicable

Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors

NCT06711978
completedphase_3

Study of Mirogabalin for Central Neuropathic Pain

NCT03901352
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07451431Phase 4

Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain

Recruiting
NCT07157852Not Applicable

The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia

Recruiting
NCT06328062Not Applicable

Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA

Recruiting
NCT06711978Not Applicable

Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors

Not Yet Recruiting
NCT03901352Phase 3

Study of Mirogabalin for Central Neuropathic Pain

Completed
NCT04094662Phase 3

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6